RU2230571C2 - Method for treating mastitis in cows - Google Patents

Abstract

FIELD: veterinary science.

SUBSTANCE: the present innovation deals with intracisternal injection of staphylococcal and streptococcal anatoxins in mixture of 25%-analgin solution at the dosage of 2 ml, 2 ml and 4 ml, correspondingly. The method is highly efficient at treating mastitis of coccal etiology in cows.

EFFECT: higher efficiency.

1 ex, 1 tbl

Description

The invention relates to the field of veterinary medicine, in particular, to a method for the targeted treatment of mastitis of coccal etiology using streptococcal and staphylococcal toxoids.

The closest analogue used for the treatment of mastitis in cows is their antibiotic therapy, which occupies a dominant position among all means of etiotropic therapy (Kuzmin G.N. Mastitis of coccal etiology in cows and rational methods of its therapy and prophylaxis. ., Voronezh, 1995, p.2.32-33).

The disadvantage of antibiotic therapy is the high resistance of the main causative agents of mastitis, staphylococci and streptococci to the antimicrobial effect of antibiotics and the negative effect of the latter on the health of consumers of dairy products.

The “Method for the prevention of mastitis” was taken as a prototype, based on the intracisternal administration of staphylococcal, streptococcal toxoids (patent No. 2116085. Method for the prevention of mastitis, authors Evglevsky A.A. et al.).

The disadvantage of using the above method for the prevention of mastitis in cows for the treatment of clinically expressed forms of inflammation of the mammary gland was the insufficient dosage and frequency of use of staphylococcal and streptococcal toxoids, which did not provide an effective antimicrobial effect on the microflora of patients with the udder and could not adequately induce the formation of rapid local antitoxic immunity with the development of clinical forms of inflammation in the mammary gland, which led to an increase in duration of treatment.

An increase in the dosage of vaccine preparations to 2 ml each, in order to avoid additional irritating effect on the inflamed tissues of the mammary gland, required dilution with physiological saline 4: 4.

The aim of the invention is to increase the efficiency and reduce the complexity of treatment.

When this goal is achieved, it is taken into account that mastitis in all cases is accompanied by the development of a local pain symptom of the inflamed lobe of the mammary gland, to reduce the latter and to provide better permeability of vaccines, the standard 25% solution of analgin produced for veterinary and medical purposes was used instead of physiological saline .

An example of the method for producing staphylococcal and streptococcal toxoids used cultures of Staphylococcus aureus and hemolytic agalactic streptococcus, the cultivation of which was carried out separately on the liquid synthetic nutrient media described in patent No. 21323882 and patent application No. 98104551 (13) 003524 (“Medium for growing , author Evglevskaya E.P. et al., Decision on the grant of a patent dated January 27, 2000).

After growth and the maximum accumulation of biomass, the grown cultures were autoclaved at 1 atm for 30 min, the biomass was separated from the culture fluid by filtration, and the latter was detoxified with 0.3% formalin for 14 days. Thus obtained native staphylococcal and streptococcal toxoids were used to treat various forms of clinically pronounced mastitis in cows with the intracisternal method of administration, the effectiveness of which is presented in the table for clarity.

Based on the results of an example of studying streptococcal and staphylococcal toxoid with the intracisternal method of administration for the treatment of clinically expressed forms of mastitis in cows, it follows that the following drug ratios have the greatest therapeutic effect: streptococcal toxoid - 2 ml, staphylococcal toxoid - 2 ml, 25% analgin solution - 4 ml .

The use of vaccine preparations is not accompanied by the acquisition of increased resistance of microorganisms to them, but rather, after the course of treatment, pathogenic forms of staphylococci and streptococci were not isolated in 10 cases in 10 days. However, the therapeutic effect in the catarrhal and purulent-catarrhal forms of mastitis was not complete.

This was due to the fact that antibiotic-resistant forms of Pseudomonas aeruginosa were isolated in 2 cases and 3 Escherichia coli in secretion of breast fractions. Thus, specific immunotherapy of clinically expressed forms of mastitis in cows during the lactation period turned out to be quite effective, induced the rapid formation of local immunity of the mammary gland, its combination with a 25% solution of analgin, used as an anesthetic drug, accelerated the course of treatment for 2-3 days.

Claims (1)

A method of treating mastitis in cows, including intracisternal administration of drugs, characterized in that staphylococcal and streptococcal toxoids are used as a drug in a mixture with a 25% analgin solution, in a dose of 2 ml, 2 ml and 4 ml, respectively.